Search research articles
Contact Us
Filters
Showing results (401-410 of 596) with videos related to
Page
of 60
Sort By:
Heart Rhythm O2
|
August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
Francis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
JACC. Heart Failure
|
March 14, 2021
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure
Marat Fudim, Manesh R Patel, Richard Boortz-Marx, et al.
JAMA Cardiology
|
November 5, 2022
Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection
E Hope Weissler, Oyomoare L Osazuwa-Peters, Melissa A Greiner, et al.
American Heart Journal
|
June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association
|
June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
George C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)
|
March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
Circulation. Cardiovascular Imaging
|
February 5, 2019
Predictive Model for High-Risk Coronary Artery Disease
James J Jang, Manjushri Bhapkar, Adrian Coles, et al.
American Heart Journal
|
September 20, 2020
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial
J Antonio Gutierrez, Gretchen M Heizer, W Schuyler Jones, et al.
The American Journal of Cardiology
|
September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
American Heart Journal
|
May 30, 2021
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease
Dennis I Narcisse, Cassie B Ford, E Hope Weissler, et al.
Page
of 60
Search research articles
Search
Showing results (401-410 of 596) with videos related to
Sort By:
Page
of 60
Heart Rhythm O2
|
August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
Francis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
JACC. Heart Failure
|
March 14, 2021
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure
Marat Fudim, Manesh R Patel, Richard Boortz-Marx, et al.
JAMA Cardiology
|
November 5, 2022
Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection
E Hope Weissler, Oyomoare L Osazuwa-Peters, Melissa A Greiner, et al.
American Heart Journal
|
June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association
|
June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
George C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)
|
March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
Circulation. Cardiovascular Imaging
|
February 5, 2019
Predictive Model for High-Risk Coronary Artery Disease
James J Jang, Manjushri Bhapkar, Adrian Coles, et al.
American Heart Journal
|
September 20, 2020
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial
J Antonio Gutierrez, Gretchen M Heizer, W Schuyler Jones, et al.
The American Journal of Cardiology
|
September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
American Heart Journal
|
May 30, 2021
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease
Dennis I Narcisse, Cassie B Ford, E Hope Weissler, et al.
Page
of 60